Switch to:
Also traded in: Canada, Germany
» Details

Insider Trades

Latest Guru Trades with IGXT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:MTFBF, NAS:AVEO, AMEX:RNN, NAS:OVAS, NAS:NTEC, NAS:DRNA, OTCPK:NWBO, NAS:RGLS, OTCPK:GRPOF, NAS:KMPH, OTCPK:AAVXF, NAS:DMPI, NAS:ZSAN, NAS:TRIL, OTCPK:THCBF, OTCPK:COTQF, AMEX:AMPE, AMEX:NBY, NAS:MTP, OTCPK:AMEUF » details
Traded in other countries:IGX.Canada, 0IL.Germany,
Intelgenx Technologies Corp., is a drug delivery company. The Company is engaged in the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies.

Intelgenx Technologies Corp., was incorporated in Delaware on July 27, 1999. The Company is a drug delivery company. It is engaged in the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies. Its product development efforts are based upon three platform technologies: Versafilm- an oral film technology, VersaTab- a multilayer tablet technology and AdVersa- a mucoadhesive tablet technology. The Oral Film technology consists of a thin (25-35 micron) polymeric film comprised of United States Pharmacopeia (USP) components that are approved by the FDA for use in food, pharmaceutical, and cosmetic products. Its multilayer tablet technology allows for the development of oral controlled-release products. The mucoadhesive tablet is a drug delivery system capable of adhering to the oral mucosa and releasing the drug onto the site of application at a controlled rate. The Company's product portfolio includes a blend of generic and branded products based on its proprietary delivery technology. Some of its products are INT0001/2004, INT0004/2006, INT0007/2006, and among others. The Company competes with pharmaceutical industries. Some of its competitors include Monosol Rx, Tesa-Labtec GmbH, BioDelivery Sciences International, Inc and LTS Lohmann Therapy Systems Corp. It is subject to change in governmental regulations, healthcare legislations, availability of financing, patent litigation and other factors.

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 38.65
IGXT's Price-to-Owner-Earnings is ranked lower than
59% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. IGXT: 38.65 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
IGXT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 26.36  Med: 35.45 Max: 42.27
Current: 38.65
26.36
42.27
PB Ratio 11.34
IGXT's PB Ratio is ranked lower than
88% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. IGXT: 11.34 )
Ranked among companies with meaningful PB Ratio only.
IGXT' s PB Ratio Range Over the Past 10 Years
Min: 4.66  Med: 10.2 Max: 90
Current: 11.34
4.66
90
PS Ratio 12.15
IGXT's PS Ratio is ranked higher than
50% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. IGXT: 12.15 )
Ranked among companies with meaningful PS Ratio only.
IGXT' s PS Ratio Range Over the Past 10 Years
Min: 4.9  Med: 15.38 Max: 97.14
Current: 12.15
4.9
97.14
Price-to-Operating-Cash-Flow 21.78
IGXT's Price-to-Operating-Cash-Flow is ranked lower than
51% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. IGXT: 21.78 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
IGXT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 14.87  Med: 36.15 Max: 58.89
Current: 21.78
14.87
58.89
Current Ratio 1.10
IGXT's Current Ratio is ranked lower than
86% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. IGXT: 1.10 )
Ranked among companies with meaningful Current Ratio only.
IGXT' s Current Ratio Range Over the Past 10 Years
Min: 0.66  Med: 4.16 Max: 11.6
Current: 1.1
0.66
11.6
Quick Ratio 1.10
IGXT's Quick Ratio is ranked lower than
83% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. IGXT: 1.10 )
Ranked among companies with meaningful Quick Ratio only.
IGXT' s Quick Ratio Range Over the Past 10 Years
Min: 0.66  Med: 4.16 Max: 11.6
Current: 1.1
0.66
11.6
Days Sales Outstanding 16.01
IGXT's Days Sales Outstanding is ranked higher than
83% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. IGXT: 16.01 )
Ranked among companies with meaningful Days Sales Outstanding only.
IGXT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 16.01  Med: 159.91 Max: 390.59
Current: 16.01
16.01
390.59

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.40
IGXT's 3-Year Average Share Buyback Ratio is ranked higher than
57% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. IGXT: -8.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IGXT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -120.3  Med: -27.95 Max: -8.4
Current: -8.4
-120.3
-8.4

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 10.63
IGXT's Price-to-Tangible-Book is ranked lower than
83% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. IGXT: 10.63 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
IGXT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 5.25  Med: 10 Max: 75
Current: 10.63
5.25
75
Price-to-Median-PS-Value 0.79
IGXT's Price-to-Median-PS-Value is ranked higher than
65% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. IGXT: 0.79 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IGXT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.4  Med: 1 Max: 5.64
Current: 0.79
0.4
5.64
Earnings Yield (Greenblatt) % -2.20
IGXT's Earnings Yield (Greenblatt) % is ranked higher than
69% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. IGXT: -2.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IGXT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.28  Med: 2.35 Max: 5.1
Current: -2.2
-2.28
5.1

More Statistics

Revenue (TTM) (Mil) $4.81
Beta1.63
Short Percentage of Float0.00%
52-Week Range $0.45 - 1.00
Shares Outstanding (Mil)64.67

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 6 6 8 17
EPS ($) -0.01 -0.02 -0.03 0.04
EPS without NRI ($) -0.01 -0.02 -0.03 0.04
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for IGXT

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Feb 09 2017
IntelGenx and Tetra Bio-Pharma Announce the Signing of a Term Sheet for the Development and... Feb 09 2017
IntelGenx Presentation Now Available for On-Demand Viewing Feb 06 2017
IntelGenx Presentation Now Available for On-Demand Viewing Feb 06 2017
Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present... Jan 30 2017
Life Sciences & Healthcare Investor Conference & Webinar: Nasdaq and OTCQX Companies Present... Jan 30 2017
/DISREGARD RELEASE: IntelGenx Technologies Corp./ Jan 30 2017
/DISREGARD RELEASE: IntelGenx Technologies Corp./ Jan 30 2017
IntelGenx to Webcast, Live, at VirtualInvestorConferences.com February 2 Jan 30 2017
IntelGenx to Webcast, Live, at VirtualInvestorConferences.com February 2 Jan 30 2017
IntelGenx Grants Stock Options Jan 19 2017
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Jan 04 2017
IntelGenx Announces Definitive Agreement with Chemo Group for a Generic CNS Tablet Jan 04 2017
IntelGenx Announces Definitive Agreement with Chemo Group for a Generic CNS Tablet Jan 04 2017
IntelGenx Announces Development and Commercialization Agreement with Endo Ventures Dec 27 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Dec 27 2016
IntelGenx Announces Development and Commercialization Agreement with Endo Ventures Dec 27 2016
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Dec 14 2016
RedHill Biopharma and IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT®... Dec 14 2016
RedHill Biopharma and IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT®... Dec 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK